SC TO-T/A: Third party tender offer statement (Amendment)
Apr 25 16:36 ET
6-K: Financial Report Q1 2024
Apr 23 06:09 ET
SC TO-T/A: Third party tender offer statement (Amendment)
Apr 18 16:33 ET
SC 13D: Statement of acquisition of beneficial ownership by individuals-Novartis BidCo AG(11.56%),Novartis Pharma AG(11.56%), etc.
Apr 18 14:37 ET
SC TO-T/A: Third party tender offer statement (Amendment)
Apr 17 16:37 ET
SC TO-T/A: Third party tender offer statement (Amendment)
Apr 16 17:11 ET
Novartis AG | SC TO-T/A: Third party tender offer statement (Amendment)
Apr 15 15:50 ET
Novartis AG | SC TO-T: Third party tender offer statement
Apr 11 06:05 ET
Novartis AG | S-8 POS: S-8 POS
Feb 15 16:20 ET
Novartis AG | SC TO-C: Written communication relating to an issuer or third party tender offer
Feb 6 16:58 ET
Novartis AG | SC TO-C: Written communication relating to an issuer or third party tender offer
Feb 5 17:09 ET
Novartis AG | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(6.1%)
Feb 2 14:22 ET
Novartis AG | 6-K: Report of foreign private issuer (related to financial reporting)
Jan 31 07:46 ET
Novartis AG | IRANNOTICE: IRANNOTICE
Jan 31 07:46 ET
Novartis AG | 6-K: Annual Report 2023 and Novartis in Society - Integrated Report 2023
Jan 31 07:46 ET
Novartis AG | 20-F: Registration statement / Annual report / Transition report
Jan 31 07:41 ET
Novartis AG | 6-K: Novartis Scemblix® Shows Superior Major Molecular Response (Mmr) Rates Vs. Standard-of-Care Tkis in Phase Iii Trial for Newly Diagnosed Patients with Chronic Myeloid Leukemia
Jan 8 00:00 ET
Novartis AG | 6-K: Novartis Investigational Iptacopan Phase Iii Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3g)
Dec 11, 2023 06:05 ET
Novartis AG | 6-K: Novartis Receives Fda Approval for Fabhalta® (Iptacopan)
Dec 5, 2023 20:19 ET
Novartis AG | 6-K: Novartis Upgrades Mid-Term Sales Growth Guidance, Showcases Its Differentiated Innovative Medicines Strategy and Robust Pipeline at R&d Day
Nov 28, 2023 06:10 ET
No Data
No Data